Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 694

1.

Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).

Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, Johnson KW.

Thromb Haemost. 2006 Jan;95(1):68-76.

PMID:
16543964
[PubMed - indexed for MEDLINE]
3.
4.

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.

Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, Powell S, Johnson KW.

Blood. 2008 Jan 15;111(2):672-9. Epub 2007 Oct 31.

PMID:
17978172
[PubMed - indexed for MEDLINE]
Free Article
5.

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.

Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE.

Blood. 2011 May 19;117(20):5514-22. doi: 10.1182/blood-2010-10-311936. Epub 2011 Mar 9.

PMID:
21389323
[PubMed - indexed for MEDLINE]
Free Article
6.

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.

Sørensen B, Ingerslev J.

J Thromb Haemost. 2004 Jan;2(1):102-10.

PMID:
14717973
[PubMed - indexed for MEDLINE]
7.

Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.

Lisman T, de Groot PG, Lambert T, Røjkjaer R, Persson E.

J Thromb Haemost. 2003 Oct;1(10):2175-8.

PMID:
14521601
[PubMed - indexed for MEDLINE]
8.

Progress in the treatment of bleeding disorders.

Bergman GE.

Thromb Res. 2011 Jan;127 Suppl 1:S3-5. doi: 10.1016/j.thromres.2010.10.007. Epub 2010 Oct 29. Review.

PMID:
21035836
[PubMed - indexed for MEDLINE]
9.

Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.

Welsch DJ, Novotny WF, Wun TC.

Thromb Res. 1991 Oct 15;64(2):213-22.

PMID:
1811340
[PubMed - indexed for MEDLINE]
10.

Ways to bypass a blocked tenase complex.

Tuddenham EG.

Thromb Haemost. 2006 Jan;95(1):1-2. No abstract available.

PMID:
16543953
[PubMed - indexed for MEDLINE]
11.

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Hilden I, Lauritzen B, Sørensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjørn SE.

Blood. 2012 Jun 14;119(24):5871-8. doi: 10.1182/blood-2012-01-401620. Epub 2012 May 4.

PMID:
22563084
[PubMed - indexed for MEDLINE]
Free Article
12.

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.

Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, Knoebl P, Gilbert JC, Schaub RG, Dockal M, McGinness KE, Pabinger I, Srivastava A.

J Thromb Haemost. 2012 Aug;10(8):1581-90. doi: 10.1111/j.1538-7836.2012.04790.x.

PMID:
22632032
[PubMed - indexed for MEDLINE]
13.
14.

Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.

Chang JY, Chantrathammachart P, Monroe DM, Key NS.

Thromb Res. 2012 Sep;130(3):e151-7. doi: 10.1016/j.thromres.2012.05.010. Epub 2012 May 30.

PMID:
22658294
[PubMed - indexed for MEDLINE]
15.

Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.

Mariani G, Bouma BN, Mazzucconi MG, Avvisati G, Di Nucci GD, Corrao D, Mandelli F.

Thromb Res. 1983 Aug 1;31(3):475-88.

PMID:
20218003
[PubMed - indexed for MEDLINE]
16.

Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.

Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O.

Blood Coagul Fibrinolysis. 1995 Jul;6(5):388-94.

PMID:
8589204
[PubMed - indexed for MEDLINE]
17.

Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.

Asatiani E, Kessler CM; Directors of the Comprehensive Hemophilia Treatment Centers in Region III.

Haemophilia. 2007 Nov;13(6):685-96. Review.

PMID:
17973844
[PubMed - indexed for MEDLINE]
18.

Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro.

Baba M, Nakajima M, Schols D, Pauwels R, Balzarini J, De Clercq E.

Antiviral Res. 1988 Sep;9(6):335-43.

PMID:
2465736
[PubMed - indexed for MEDLINE]
19.

Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.

Nordfang O, Valentin S, Beck TC, Hedner U.

Thromb Haemost. 1991 Oct 1;66(4):464-7.

PMID:
1796397
[PubMed - indexed for MEDLINE]
20.

Current therapy for rare factor deficiencies.

Di Paola J, Nugent D, Young G.

Haemophilia. 2001 Jan;7 Suppl 1:16-22. Review.

PMID:
11240614
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk